HC Wainwright & Co. Upholds Buy Rating for Vor Biopharma (VOR)
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 15 2025
0mins
Source: NASDAQ.COM
Analyst Recommendation: HC Wainwright & Co. has maintained a Buy recommendation for Vor Biopharma, with an average one-year price target of $47.68/share, indicating a potential upside of 373.07% from its current price of $10.08/share.
Fund Sentiment: There are currently 67 funds reporting positions in Vor Biopharma, with a slight decrease in ownership by 5.63% over the last quarter, while the average portfolio weight dedicated to VOR has increased by 75.40%.
Ownership Breakdown: Major shareholders include Ra Capital Management (11.76% ownership), Vanguard Total Stock Market Index Fund (8.22%), and several other funds with no changes in their holdings over the last quarter.
Market Outlook: The put/call ratio for Vor Biopharma is 0.53, suggesting a bullish sentiment among investors, despite a significant decrease in total shares owned by institutions by 92.17% in the last three months.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on VOR
Wall Street analysts forecast VOR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VOR is 38.67 USD with a low forecast of 9.00 USD and a high forecast of 55.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 13.740
Low
9.00
Averages
38.67
High
55.00
Current: 13.740
Low
9.00
Averages
38.67
High
55.00
About VOR
Vor Biopharma Inc. is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a dual-target fusion protein, through Phase III clinical development and commercialization to address serious autoantibody-driven conditions worldwide. Telitacicept is an investigational recombinant fusion protein designed to treat autoimmune diseases by selectively inhibiting BLyS (BAFF) and APRIL - two cytokines essential to B cell and plasma cell survival. This dual-target mechanism reduces autoreactive B cells and autoantibody production, key drivers of autoimmune pathology. Telitacicept is approved in China for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia gravis (gMG). A global Phase III clinical trial in gMG is underway across the United States, Europe, and South America to support potential approval in the United States and Europe.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Vor Biopharma Appoints Two New Board Members to Support $150M PIPE Financing
- New Board Members: Vor Biopharma has appointed Andrew Levin from RA Capital and Wouter Joustra from Forbion to its Board of Directors, aiming to leverage their extensive experience in life sciences investment and financing strategy to advance the company's global Phase 3 clinical trials.
- Financing Context: This board change follows the company's announcement of a $150 million PIPE financing, reflecting a strategic emphasis on capital allocation and long-term growth, which is expected to enhance investor confidence and drive shareholder value.
- Strategic Development: The addition of Levin and Joustra will provide Vor Biopharma with valuable industry insights, particularly in advancing the clinical programs and commercialization of telitacicept, further solidifying the company's market position in its field.
- Industry Impact: Vor Biopharma focuses on treating autoimmune diseases, and the development of telitacicept will help address serious autoantibody-driven conditions globally, which is anticipated to present significant market opportunities and growth potential for the company.
Continue Reading
Vor Bio Secures $150 Million in Private Placement at $10.81 per Share
- Financing Scale: Vor Bio has entered into a securities purchase agreement to sell 13,876,032 shares at $10.81 each, anticipating gross proceeds of approximately $150 million, which will significantly bolster the company's financial resources in the biotechnology sector.
- Investor Participation: The financing attracted participation from both new and existing institutional investors, including RA Capital Management and Forbion, indicating strong market confidence in Vor Bio's clinical-stage biotechnology and potentially paving the way for future collaborations and growth.
- Board Changes: As part of the private placement, Forbion is granted the right to appoint one director to Vor Bio's board, which not only enhances investor influence but may also provide strategic guidance and resource support for the company.
- Use of Funds: Vor Bio intends to utilize the net proceeds to advance the clinical development of telitacicept, including the ongoing global Phase 3 trial for myasthenia gravis, demonstrating the company's strong commitment to drug development and addressing the urgent market need for treatments for autoimmune diseases.
Continue Reading